Impact of Extending Beta-Lactam Infusions on IV Access Requirements.

IF 2.7 Q4 Medicine
Critical care explorations Pub Date : 2025-08-04 eCollection Date: 2025-08-01 DOI:10.1097/CCE.0000000000001299
Kirstin J Kooda, Julia Nelson, Sara E Ausman, Christina G Rivera, Omar M Abu Saleh, Andrew D Rule, Ryan W Stevens, Micaela N Warfield, Yanjun Zhao, Erin F Barreto
{"title":"Impact of Extending Beta-Lactam Infusions on IV Access Requirements.","authors":"Kirstin J Kooda, Julia Nelson, Sara E Ausman, Christina G Rivera, Omar M Abu Saleh, Andrew D Rule, Ryan W Stevens, Micaela N Warfield, Yanjun Zhao, Erin F Barreto","doi":"10.1097/CCE.0000000000001299","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine if extended infusion (EI; over > 3 hr) beta-lactam therapy increased IV access requirements compared with traditional dosing (TD; over 30 min). Eighty-six adult ICU patients treated with TD anti-pseudomonal beta-lactams who underwent therapeutic drug monitoring (TDM) were included. Patients who transitioned from TD to EI after TDM (EI group) were matched 1:1 to patients who remained on TD. In the primary analysis, the median (interquartile range) total number of lumens in the 24 hours before TDM compared with the 48 hours after TDM were similar between groups (pre: TD 3 [2-5] vs. EI 4 [3-5]; p = 0.22 and post: TD 3 [2-4] vs. EI 4 [3-5]; p = 0.05). Delivery of beta-lactams via EI was not associated with a need for more IV access. Practical challenges such as access should not limit use of EI beta-lactams when indicated.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"7 8","pages":"e1299"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324035/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to determine if extended infusion (EI; over > 3 hr) beta-lactam therapy increased IV access requirements compared with traditional dosing (TD; over 30 min). Eighty-six adult ICU patients treated with TD anti-pseudomonal beta-lactams who underwent therapeutic drug monitoring (TDM) were included. Patients who transitioned from TD to EI after TDM (EI group) were matched 1:1 to patients who remained on TD. In the primary analysis, the median (interquartile range) total number of lumens in the 24 hours before TDM compared with the 48 hours after TDM were similar between groups (pre: TD 3 [2-5] vs. EI 4 [3-5]; p = 0.22 and post: TD 3 [2-4] vs. EI 4 [3-5]; p = 0.05). Delivery of beta-lactams via EI was not associated with a need for more IV access. Practical challenges such as access should not limit use of EI beta-lactams when indicated.

Abstract Image

延长β -内酰胺输注对静脉注射需求的影响。
本研究旨在确定延长输注(EI;与传统剂量相比,β -内酰胺治疗增加了静脉通路需求(TD;超过30分钟)。本研究纳入86例接受TD抗假单胞菌β -内酰胺类药物治疗并接受治疗药物监测(TDM)的ICU患者。TDM后从TD过渡到EI的患者(EI组)与继续使用TD的患者1:1匹配。在初步分析中,TDM前24小时与TDM后48小时的中位数(四分位数范围)总流明数在两组之间相似(TDM前:TDM 3 [2-5] vs. EI 4 [3-5];p = 0.22后:TD 3 [2-4] vs EI 4 [3-5];P = 0.05)。β -内酰胺经EI输送与需要更多静脉注射无关。实际的挑战,如获取不应限制使用EI β -内酰胺时指出。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信